CD-101 (Immunicum)

N/A

Report date: 2025/01/26 19:30:39

Base Information

Drug NameCD-101 (Immunicum)
Drug Alias NameCD-101 (Mendus AB)CD3-targeted adoptive T-cell therapy (Mendus)CD3-targeted adoptive T-cell therapy (Immunicum)CD3-targeted adoptive T-cell therapy (Immunicu)CD3-targeted adoptive T-cell therapy (Mendus AB)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMendus AB
China Registration ClassN/A

Develop Information

Active CompaniesMendus AB
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A